Citius Oncology (CTOR) Competitors $1.99 +0.10 (+5.29%) Closing price 04:00 PM EasternExtended Trading$1.98 -0.01 (-0.70%) As of 05:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CTOR vs. PVLA, SAGE, SNDL, ARVN, OPT, SVRA, BCYC, SEPN, ZVRA, and AUTLShould you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Palvella Therapeutics (PVLA), Sage Therapeutics (SAGE), SNDL (SNDL), Arvinas (ARVN), Opthea (OPT), Savara (SVRA), Bicycle Therapeutics (BCYC), Septerna (SEPN), Zevra Therapeutics (ZVRA), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Citius Oncology vs. Its Competitors Palvella Therapeutics Sage Therapeutics SNDL Arvinas Opthea Savara Bicycle Therapeutics Septerna Zevra Therapeutics Autolus Therapeutics Palvella Therapeutics (NASDAQ:PVLA) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations. Do analysts rate PVLA or CTOR? Palvella Therapeutics currently has a consensus price target of $58.50, suggesting a potential upside of 8.82%. Citius Oncology has a consensus price target of $3.00, suggesting a potential upside of 50.75%. Given Citius Oncology's higher probable upside, analysts plainly believe Citius Oncology is more favorable than Palvella Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palvella Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Citius Oncology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation & earnings, PVLA or CTOR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalvella TherapeuticsN/AN/A-$17.43M-$12.10-4.44Citius OncologyN/AN/AN/AN/AN/A Does the media favor PVLA or CTOR? In the previous week, Palvella Therapeutics had 4 more articles in the media than Citius Oncology. MarketBeat recorded 7 mentions for Palvella Therapeutics and 3 mentions for Citius Oncology. Palvella Therapeutics' average media sentiment score of 0.69 beat Citius Oncology's score of 0.25 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of PVLA or CTOR? 40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 20.5% of Palvella Therapeutics shares are held by insiders. Comparatively, 4.6% of Citius Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, PVLA or CTOR? Palvella Therapeutics has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500. Comparatively, Citius Oncology has a beta of 3, indicating that its stock price is 200% more volatile than the S&P 500. Is PVLA or CTOR more profitable? Citius Oncology's return on equity of -51.93% beat Palvella Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Palvella TherapeuticsN/A -62.30% -43.34% Citius Oncology N/A -51.93%-22.17% SummaryPalvella Therapeutics beats Citius Oncology on 6 of the 11 factors compared between the two stocks. Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTOR vs. The Competition Export to ExcelMetricCitius OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$155.96M$3.09B$5.74B$9.77BDividend YieldN/A2.24%4.40%4.08%P/E RatioN/A20.7830.4126.04Price / SalesN/A347.65428.97104.72Price / CashN/A43.2325.7828.79Price / Book3.119.809.706.08Net IncomeN/A-$54.08M$3.27B$265.64M7 Day Performance17.06%4.93%3.94%3.11%1 Month Performance1.02%3.64%3.81%0.39%1 Year Performance-2.45%8.20%31.26%18.52% Citius Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTORCitius Oncology1.338 of 5 stars$1.99+5.3%$3.00+50.8%+1.1%$155.96MN/A0.00N/APVLAPalvella Therapeutics1.9239 of 5 stars$49.55+4.8%$57.10+15.2%N/A$548.02M$42.81M-4.10N/ASAGESage Therapeutics3.3708 of 5 stars$8.68flat$7.85-9.6%N/A$543.54M$41.24M-1.78690SNDLSNDL1.7091 of 5 stars$2.14+5.7%$4.00+87.3%+13.7%$530.81M$671.81M-8.012,516Gap UpARVNArvinas4.0029 of 5 stars$7.20+1.6%$19.76+174.4%-71.4%$524.95M$263.40M-7.08420Positive NewsOPTOpthea0.2284 of 5 stars$3.41+7.2%$1.33-60.9%+18.8%$524.83M$120K0.008Positive NewsUpcoming EarningsGap UpHigh Trading VolumeSVRASavara3.2499 of 5 stars$3.03-0.8%$6.17+103.9%-28.1%$523.36MN/A-6.0620BCYCBicycle Therapeutics3.2713 of 5 stars$7.59+2.1%$22.22+192.6%-68.2%$514.90M$19.28M-2.12240Positive NewsSEPNSepterna1.7011 of 5 stars$11.57-1.3%$26.75+131.2%N/A$514.41M$1.08M-1.14N/AZVRAZevra Therapeutics3.377 of 5 stars$9.17-0.4%$23.71+158.7%+30.4%$514.15M$23.61M-43.6220AUTLAutolus Therapeutics2.4748 of 5 stars$1.87-0.5%$9.12+387.7%-59.9%$497.68M$10.12M-2.23330 Related Companies and Tools Related Companies Palvella Therapeutics Competitors Sage Therapeutics Competitors SNDL Competitors Arvinas Competitors Opthea Competitors Savara Competitors Bicycle Therapeutics Competitors Septerna Competitors Zevra Therapeutics Competitors Autolus Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTOR) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access